During the past decade, Azienda Ospedaliera Universitaria Integrata Verona conducted 179 clinical trials. In the 10-year time frame, 179 clinical trials started and 41 clinical trials were completed, i.e. on average, 22.9% percent of trials that started reached the finish line to date. In the past 5 years, 107 clinical trials started and 34 clinical trials were completed. i.e. 31.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Universitaria Integrata Verona" #1 sponsor was "Azienda Ospedaliera Universitaria Integrata Verona" with 31 trials, followed by "Universita di Verona" with 13 trials sponsored, "Bayer" with 11 trials sponsored, "Celgene" with 9 trials sponsored and "Vertex Pharmaceuticals Incorporated" with 9 trials sponsored. Other sponsors include 139 different institutions and companies that sponsored additional 101 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Universitaria Integrata Verona" #1 collaborator was "Azienda Ospedaliera Universitaria Integrata Verona" with 4 trials as a collaborator, "Cystic Fibrosis Foundation" with 4 trials as a collaborator, "Agenzia Italiana del Farmaco" with 3 trials as a collaborator, "Universita di Verona" with 3 trials as a collaborator and "Azienda Sanitaria-Universitaria Integrata di Udine" with 2 trials as a collaborator. Other collaborators include 67 different institutions and companies that were collaborators in the rest 76 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Universitaria Integrata Verona" are "Cystic Fibrosis" (17 trials), "Breast Cancer" (5 trials), "Coronary Artery Disease" (4 trials), "Endometriosis" (4 trials) and "Multiple Sclerosis" (4 trials). Many other conditions were trialed in "Azienda Ospedaliera Universitaria Integrata Verona" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Universitaria Integrata Verona" are "Drug" (132 trials), "Device" (34 trials), "Other" (30 trials), "Procedure" (13 trials) and "Biological" (9 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (40 trials), "Docetaxel" (7 trials), "Gemcitabine" (7 trials), "IVA" (7 trials) and "ELX/TEZ/IVA" (5 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Universitaria Integrata Verona" are 198 trials for "All" genders, 15 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Universitaria Integrata Verona". 2 are not yet recruiting, 60 are recruiting, 24 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 85 completed trials in Azienda Ospedaliera Universitaria Integrata Verona, 1 suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Universitaria Integrata Verona, 12 "Phase 1" clinical trials were conducted, 42 "Phase 2" clinical trials and 82 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 42 trials that are defined as “Not Applicable".

Azienda Ospedaliera Universitaria Integrata Verona has several departments that took part in Clinical trials: "A.O.U.I. VERONA-OSPEDALE BORGO TRENTO; ONCOLODIA MEDICA-d.O." - 8 trials, "Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi" - 38 trials, "A.O.U.I. VERONA-OSPEDALE POLICLINICO G.B. ROSSI BORGO ROMA;ONCOLOGIA MEDICA-d.U." - 5 trials, "S.S.O. di Riabilitazione dell'Ospedale Policlinico" - 4 trials